HC Wainwright Issues Negative Estimate for VNDA Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at HC Wainwright decreased their Q3 2026 earnings estimates for shares of Vanda Pharmaceuticals in a report issued on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of $0.06 for the quarter, down from their previous estimate of $0.10. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q4 2026 earnings at $0.13 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $50.04 million during the quarter, compared to analyst estimates of $45.13 million.

Other equities analysts have also issued research reports about the stock. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday.

Vanda Pharmaceuticals Trading Up 5.9%

NASDAQ:VNDA opened at $4.16 on Thursday. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $6.75. The company has a 50-day moving average of $4.44 and a 200-day moving average of $4.63. The firm has a market cap of $245.17 million, a price-to-earnings ratio of -13.00 and a beta of 0.69.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors have recently made changes to their positions in VNDA. Millennium Management LLC raised its position in Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after acquiring an additional 1,470,898 shares in the last quarter. Royal Bank of Canada raised its position in Vanda Pharmaceuticals by 34.3% during the first quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 14,232 shares in the last quarter. MetLife Investment Management LLC raised its position in Vanda Pharmaceuticals by 18.9% during the first quarter. MetLife Investment Management LLC now owns 32,816 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 5,210 shares in the last quarter. Stonepine Capital Management LLC raised its position in Vanda Pharmaceuticals by 40.6% during the first quarter. Stonepine Capital Management LLC now owns 35,148 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 10,148 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in Vanda Pharmaceuticals during the first quarter valued at approximately $170,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was acquired at an average cost of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the acquisition, the chief executive officer now owns 2,331,730 shares in the company, valued at $10,399,515.80. This trade represents a 0.43% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought a total of 32,000 shares of company stock worth $151,180 over the last ninety days. 10.00% of the stock is currently owned by company insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.